RO123269B1 - Utilizarea meta-arsenitului de sodiu pentru tratamentul tumorilor solide - Google Patents

Utilizarea meta-arsenitului de sodiu pentru tratamentul tumorilor solide Download PDF

Info

Publication number
RO123269B1
RO123269B1 ROA200400890A RO200400890A RO123269B1 RO 123269 B1 RO123269 B1 RO 123269B1 RO A200400890 A ROA200400890 A RO A200400890A RO 200400890 A RO200400890 A RO 200400890A RO 123269 B1 RO123269 B1 RO 123269B1
Authority
RO
Romania
Prior art keywords
tumor
arsenite
treatment
sodium
solid
Prior art date
Application number
ROA200400890A
Other languages
English (en)
Romanian (ro)
Inventor
Sang Bong Lee
Yong Jin Yang
Original Assignee
Komipharm International Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29244880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RO123269(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Komipharm International Co., Ltd. filed Critical Komipharm International Co., Ltd.
Publication of RO123269B1 publication Critical patent/RO123269B1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ROA200400890A 2002-04-10 2002-04-10 Utilizarea meta-arsenitului de sodiu pentru tratamentul tumorilor solide RO123269B1 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2002/000231 WO2003086424A1 (en) 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Publications (1)

Publication Number Publication Date
RO123269B1 true RO123269B1 (ro) 2011-05-30

Family

ID=29244880

Family Applications (1)

Application Number Title Priority Date Filing Date
ROA200400890A RO123269B1 (ro) 2002-04-10 2002-04-10 Utilizarea meta-arsenitului de sodiu pentru tratamentul tumorilor solide

Country Status (25)

Country Link
US (1) US20050106262A1 (cg-RX-API-DMAC7.html)
EP (2) EP2042182B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005525397A (cg-RX-API-DMAC7.html)
CN (1) CN1298332C (cg-RX-API-DMAC7.html)
AP (1) AP2004003167A0 (cg-RX-API-DMAC7.html)
AU (2) AU2002253713B2 (cg-RX-API-DMAC7.html)
BG (1) BG66356B1 (cg-RX-API-DMAC7.html)
BR (1) BR0215689A (cg-RX-API-DMAC7.html)
CA (1) CA2481602C (cg-RX-API-DMAC7.html)
CY (1) CY1114422T1 (cg-RX-API-DMAC7.html)
DK (2) DK2042182T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP045408A (cg-RX-API-DMAC7.html)
ES (2) ES2425418T3 (cg-RX-API-DMAC7.html)
FI (1) FI1496918T3 (cg-RX-API-DMAC7.html)
HU (1) HU230851B1 (cg-RX-API-DMAC7.html)
IL (2) IL164470A0 (cg-RX-API-DMAC7.html)
LT (1) LT1496918T (cg-RX-API-DMAC7.html)
MX (1) MXPA04009898A (cg-RX-API-DMAC7.html)
NO (1) NO335317B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ536452A (cg-RX-API-DMAC7.html)
PT (2) PT2042182E (cg-RX-API-DMAC7.html)
RO (1) RO123269B1 (cg-RX-API-DMAC7.html)
TN (1) TNSN04198A1 (cg-RX-API-DMAC7.html)
UA (1) UA80426C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003086424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024492A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20100249210A1 (en) * 2008-09-30 2010-09-30 Michael Bastiani Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
CA2772411C (en) * 2009-09-10 2017-08-22 Kominox, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
EP2477635A4 (en) * 2009-09-18 2013-03-27 Kominox Inc METHODS OF TREATING CEREBRAL TUMORS
CN101695501B (zh) * 2009-10-10 2013-08-14 广汉恒宇新材料有限公司 一种纳米尺寸亚砷酸的壳聚糖包载体及其制造方法
KR102868121B1 (ko) 2018-03-22 2025-10-14 코미팜 인터내셔널 오스트레일리아 피티와이 엘티디 메타 아비산염을 포함하는 약학 조성물 및 제조 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN1119152C (zh) * 1998-08-02 2003-08-27 哈尔滨医科大学第一临床医学院 治疗消化系统肿瘤注射液及其应用

Also Published As

Publication number Publication date
DK2042182T3 (da) 2013-08-26
MXPA04009898A (es) 2005-06-20
BR0215689A (pt) 2005-02-01
ES2944907T3 (es) 2023-06-27
EP2042182B1 (en) 2013-05-22
NO335317B1 (no) 2014-11-10
CA2481602A1 (en) 2003-10-23
ECSP045408A (es) 2006-03-01
US20050106262A1 (en) 2005-05-19
CY1114422T1 (el) 2016-08-31
PT2042182E (pt) 2013-08-28
DK1496918T3 (da) 2023-05-15
NZ536452A (en) 2007-06-29
PT1496918T (pt) 2023-05-25
EP1496918B1 (en) 2023-02-08
BG108932A (en) 2005-11-30
BG66356B1 (bg) 2013-09-30
HU230851B1 (en) 2018-09-28
EP2042182A1 (en) 2009-04-01
AU2008255139B2 (en) 2013-10-03
IL164470A (en) 2010-12-30
IL164470A0 (en) 2005-12-18
AU2008255139A1 (en) 2009-01-08
TNSN04198A1 (en) 2007-03-12
HUP0500199A2 (en) 2007-02-28
WO2003086424A1 (en) 2003-10-23
CN1625407A (zh) 2005-06-08
HUP0500199A3 (en) 2008-03-28
CN1298332C (zh) 2007-02-07
ES2425418T3 (es) 2013-10-15
EP1496918A1 (en) 2005-01-19
JP2005525397A (ja) 2005-08-25
AP2004003167A0 (en) 2004-12-31
AU2002253713B2 (en) 2008-09-18
AU2002253713A1 (en) 2003-10-27
UA80426C2 (en) 2007-09-25
LT1496918T (lt) 2023-05-25
NO20044573L (no) 2004-10-22
CA2481602C (en) 2011-06-21
FI1496918T3 (fi) 2023-05-11

Similar Documents

Publication Publication Date Title
Balsa et al. Anticancer and antimetastatic activity of copper (II)-tropolone complex against human breast cancer cells, breast multicellular spheroids and mammospheres
Gibson A matter of balance between life and death: targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy
Kosmider et al. Flavonoid compounds: A review of anticancer properties and interactions with cis‐diamminedichloroplatinum (ii)
RO123269B1 (ro) Utilizarea meta-arsenitului de sodiu pentru tratamentul tumorilor solide
Icsel et al. Zn (II), Cd (II) and Hg (II) saccharinate complexes with 2, 6-bis (2-benzimidazolyl) pyridine as promising anticancer agents in breast and lung cancer cell lines via ROS-induced apoptosis
Zhang et al. Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin-or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells
Ong et al. Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and-dependent cytotoxic potentiation
Bai et al. Novel oxovanadium complex VO (hntdtsc)(NPIP): Anticancer activity and mechanism of action on HeLa cells
Aher et al. Cytotoxic behavior of binuclear silver N-heterocyclic carbenes in HCT 116 cells and influence of substitution on cytotoxicity
RU2310460C2 (ru) Фармацевтическая композиция для лечения злокачественной опухоли, содержащая арсенит натрия
Sadeghi-Aliabadi et al. Cytotoxicity and antitumor properties of a marine compound, HESA-A, on cancer cells.
US11166908B2 (en) Composition for preparing an anti-tumour agent and a method for preparing an anti-tumour agent on the basis of same
CN114522178A (zh) 藤黄酸联合盐酸阿霉素在制备抗t细胞淋巴瘤药物中的应用
Verma et al. Dietary Ascorbic Acid-Mediated Augmentation of Antitumor Activity and Protection Against Toxicities Induced by Cis-Diamminedichloroplatinum-(II) in Daltons Lymphoma-Bearing Mice
Maier et al. The cytotoxic interaction of inorganic trace elements with EDTA and cisplatin in sensitive and resistant human ovarian cancer cells
Alonso et al. Sensitisation of Ehrlich ascitic tumour cells to methotrexate by inhibiting glutaminase
RU2358721C1 (ru) Антинеопластический препарат (варианты)
RU2721771C1 (ru) Применение композиции наночастиц оксида меди и N-ацетилцистеина для индукции гибели клеток хронического миелоидного лейкоза
Vidal-Valenzuela et al. ANTIANGIOGENIC POTENTIAL OF AN ANTHRAQUINONE METABOLITE ISOLATED FROM A MARINE FUNGUS
Bai et al. Novel Oxovanadium Complex VO (hntdtsc)(NPIP): Anticancer Activity and Mechanism of Action on
Brezar et al. Evaluation of platinum (II) complexes with 8-Hydroxyquinoline derivative in Electrochemotherapy: Comparative sensitivity of different Cancer cell lines
SINGH et al. Mitochondria as a target for combination cancer-chemotherapy
Hussain et al. Cytotoxicity of Cisplatin and Carboplatin Used Alone and in Combination with the Other Anticancer Drugs in the Mouse Embryo C3H10T½ Cell Line
Küpeli et al. Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma
du Plessis-Stoman An investigation of the in vitro anticancer properties of selected platinum compounds